. contributed equally to this manuscript.
BACKGROUND AND PURPOSEGlucagon-like peptide-1 (GLP-1) analogues improve glycaemic control in type 2 diabetic (T2D) patients and cause weight loss in obese subjects by as yet unknown mechanisms. We recently demonstrated that the GLP-1 receptor, which is present in adipocytes and the stromal vascular fraction of human adipose tissue (AT), is up-regulated in AT of insulin-resistant morbidly obese subjects compared with healthy lean subjects. The aim of this study was to explore the effects of in vitro and in vivo administration of GLP-1 and its analogues on AT and adipocyte functions from T2D morbidly obese subjects.
EXPERIMENTAL APPROACHWe analysed the effects of GLP-1 on human AT and isolated adipocytes in vitro and the effects of GLP-1 mimetics on AT of morbidly obese T2D subjects in vivo.
KEY RESULTSGLP-1 down-regulated the expression of lipogenic genes when administered during in vitro differentiation of human adipocytes from morbidly obese patients. GLP-1 also decreased the expression of adipogenic/lipogenic genes in AT explants and mature adipocytes, while increasing that of lipolytic markers and adiponectin. In 3T3-L1 adipocytes, GLP-1 decreased free cytosolic Ca 2+ concentration ([Ca 2+ ] i ). GLP-1-induced responses were only partially blocked by GLP-1 receptor antagonist exendin (9-39). Moreover, administration of exenatide or liraglutide reduced adipogenic and inflammatory marker mRNA in AT of T2D obese subjects.
CONCLUSIONS AND IMPLICATIONSOur data suggest that the beneficial effects of GLP-1 are associated with changes in the adipogenic potential and ability of AT to expand, via activation of the canonical GLP-1 receptor and an additional, as yet unknown, receptor.Abbreviations ADRP, adipocyte differentiation-related protein; AT, adipose tissue; ATGL, adipose triglyceride lipase; BMI, body mass index; FABP4, fatty acid binding protein 4; FASN, fatty acid synthase; GLP-1, glucagon-like peptide-1; HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; MO, morbidly obese; SAT, subcutaneous AT; SREBP1, sterol regulatory element-binding transcription factor 1; T2D, type 2 diabetic; VAT, visceral AT